BioSpace News Archive

Laboratory accident is dangerous thing that can even result in death. Here are the top science mishaps that took place till today. So, let’s have a look at them.

In the meantime, here are a few things you can do to fill your resume while you’re in between jobs.

Bayer Plc launches LifeHub UK as part of a global network of Bayer global innovation hubs. LifeHub UK is designed to accelerate and optimise disease detection and data-driven drug discovery by developing Artificial Intelligence (AI)-enabled imaging solutions.

Clinigen Group plc has launched a Managed Access Program for Progenics Pharmaceuticals, Inc., an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, to provide AZEDRA® via a global Managed Access Program, outside the United States.

Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in life science microbiome investment, is pleased to provide an update on its Health for Life investments for the period July 2019 to September 2019.

Biocon Biologics in-licenses an early-stage biosimilar asset, will undertake development, manufacturing and commercialization under its own label

Summit Therapeutics plc a leader in new mechanism antibiotic innovation, announces that Valerie Andrews, a Non-Executive Director, is stepping down from the board of the Company.

Expands on existing collaboration agreement with Bayer to accelerate the development of new treatments for cardiovascular disease using clinical AI

Sydney, Australia, 10 October 2019: Recce Pharmaceuticals Ltd, developing a new class of synthetic antibiotics, is pleased to announce it has raised AU$6,768,444.28 in a placement to institutional, professional and sophisticated investors that will result in 26,032,478 fully paid ordinary shares being issued at AU$0.26 per share

MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, announces an update on progress in its Phase IIa clinical study.